- Home
- BDRX vs ONCO Comparison
BDRX vs ONCO Comparison
Compare BDRX & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BDRX | ONCO |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0M | 4.3M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | BDRX | ONCO |
|---|---|---|
| Price | $2.14 | $1.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 981.2K | 57.7K |
| Earning Date | 09-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,223,751.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.06 | $1.37 |
| 52 Week High | $92.00 | $88.40 |
Technical Indicators
Market Signals| Indicator | BDRX | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 39.87 |
| Support Level | N/A | $1.48 |
| Resistance Level | N/A | $1.61 |
| Average True Range (ATR) | 0.00 | 0.14 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 0.00 | 45.10 |
Price Performance
Historical ComparisonAbout BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.